Sugi Predict

Sugi Predict / Compounds / SCHEMBL361599

SCHEMBL361599

SCHEMBL361599

O=C1CCCC1c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 1/20 0.48
▸ CRBN Q96SW2 1/20 0.48
▸ IGF1R P08069 1/20 0.47
▸ ALOX15 P16050 1/20 0.47
▸ TP53 P04637 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ SLC18A3 Q16572 1/20 0.45
▸ MCL1 Q07820 1/20 0.43
▸ CTRB1 P17538 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ CFTR P13569 1/20 0.40
▸ GOPC Q9HD26 1/20 0.40
▸ HAO1 Q9UJM8 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ MT-CO2 P00403 1/20 0.40
▸ ALOX5 P09917 1/20 0.40
▸ PSEN1 P49768 1/20 0.38
▸ PSEN2 P49810 1/20 0.38
▸ APH1B Q8WW43 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15874652 0.94 SLC18A3 (0.51) DDB1CRBNIGF1RALOX15TP53
SCHEMBL190786 0.94 SLC18A3 (0.51) DDB1CRBNIGF1RALOX15TP53
SCHEMBL9328018 0.94 SLC18A3 (0.51) DDB1CRBNIGF1RALOX15TP53
Hydrogen Peroxide SCHEMBL14842506 0.92 MCL1 (0.53) DDB1CRBNIGF1RALOX15TP53
SCHEMBL30882060 0.92 SLC18A3 (0.50) DDB1CRBNIGF1RALOX15TP53
SCHEMBL15660493 0.92 SLC18A3 (0.50) DDB1CRBNIGF1RALOX15TP53
SCHEMBL4063122 0.92 SLC18A3 (0.50) DDB1CRBNIGF1RALOX15TP53
SCHEMBL28417815 0.92 SLC18A3 (0.50) DDB1CRBNIGF1RALOX15TP53
SCHEMBL15874614 0.92 SLC18A3 (0.50) DDB1CRBNIGF1RALOX15TP53
Formaldehyde SCHEMBL28906285 0.90 SLC18A3 (0.49) DDB1CRBNIGF1RALOX15TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114605240-A Preparation method of esketamine hydrochloride synthesis intermediate 宜昌人福药业有限责任公司 2022-06-10 — — CN claimed
CN-106431934-A Method for synthesizing S-shaped amino compound 陈永军 2017-02-22 — — CN claimed
CN-106397216-A Method for synthesizing medical intermediates 陈永军 2017-02-15 — — CN claimed
US-20240391900-A1 RIP1 KINASE INHIBITOR AND USE THEREOF SIRONAX (BEIJING) CO., LTD. (CN) 2024-11-28 — — US disclosed
US-20240368001-A1 SALT RECOVERY SOLUTION AND PROCESSES OF USE THEREOF AQUAFORTUS TECHNOLOGIES LIMITED (NZ) 2024-11-07 — — US disclosed
US-11987506-B2 Salt recovery solution and processes of use thereof AQUAFORTUS TECHNOLOGIES LIMITED (NZ) 2024-05-21 — — US disclosed
US-20240158340-A1 PHOTOCATALYTIC ARYLATION OF CARBONYL COMPOUNDS AND METHODS FOR USING THE SAME ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA 2024-05-16 — — US disclosed
US-20230373974-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373974-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373974-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230257284-A1 SALT RECOVERY SOLUTION AND PROCESSES OF USE THEREOF AQUAFORTUS TECHNOLOGIES LIMITED (NZ) 2023-08-17 — — US disclosed
US-4920221-A CENTRAL NERVOUS SYSTEM ACTIVE AGENTS PFIZER INC. (US) 1990-04-24 — — US disclosed
US-4642373-A Substituted dodecahydrotripheylenes, and decahydropyrrolo[1,2-f]phenanthridines as CNS agents PFIZER INC. (US) 1987-02-10 — — US disclosed
US-4576964-A ANALGESICS, ANTIEMETICS PFIZER INC. (US) 1986-03-18 — — US disclosed
US-4476131-A ANTIEMETICS, ANALGESICS PFIZER INC. (US) 1984-10-09 — — US disclosed
US-4473704-A ANALGESICS, ANTIEMETICS PFIZER INC. (US) 1984-09-25 — — US disclosed
US-4350685-A ASTHMA TREATMENT SMITHKLINE CORPORATION (US) 1982-09-21 — — US disclosed
US-4286068-A POLYMERIC CATALYST CONTAINING ARSENIC ALLIED CHEMICAL CORPORATION (US) 1981-08-25 — — US disclosed
US-4259527-A OXIDATION OF SECONDARY ALCOHOLS TO KETONES WITH HYDROGEN PEROXIDE ALLIED CHEMICAL CORPORATION (US) 1981-03-31 — — US disclosed
US-4171313-A OF ALICYCLIC KETONES TO LACTONES, W-HYDROXY ACIDS AND ESTERS USING HYDROGEN PEROXIDE AS AN OXIDIZING AGENT ALLIED CHEMICAL CORPORATION (US) 1979-10-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158340-A1 PHOTOCATALYTIC ARYLATION OF CARBONYL COMPOUNDS AND METHODS FOR USING THE SAME AHR, CBR3, AADAC DDB1 4218/4885CRBN 500/4885IGF1R 3038/4885
US-20230373974-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B DDB1 2531/4885CRBN 3246/4885IGF1R 3500/4885
US-20240391900-A1 RIP1 KINASE INHIBITOR AND USE THEREOF RIPK1, RIPK2, RIPK4 DDB1 655/4885CRBN 3436/4885IGF1R 1482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.